Document is current

Article History

Accepted: 19 January 2022

First Online: 16 March 2022

Declarations

:

: DFG-German Research Foundation (WE 1184/15-1).

: The study was approved by the ethics committees at the Medical Faculty Mannheim, Heidelberg University, and at the University of Witten-Herdecke.

: The data can only be provided to other researchers upon submission of a written request and evaluation by our study group.

: MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Bristol Myers, Bayer, Boehringer-Ingelheim, LEO, Mundipharma, Novartis, Pfizer, Polyphor, Helsinn, Allergan, Allecra, Novo-Nordisk, Heel, AstraZeneca, Roche, Santhera, Sanofi-Aventis, Shire, Berlin-Chemie und Daichii-Sankyo. HF received a grant from Paul-Kurth-Stiftung. HB, CW, AKS, and FP declare that they have no conflicts of interest.

: Written consent for participation by patients or their proxies was provided [].

: Consent for publication was provided by AKS, CW, HB, HF, MW, and FP.

: Please see our data-sharing policies above.

: Not applicable.

: Original study conduct: MW, FP, HF, HB, CW. Design and ideas: MW, FP, AKS. Data analysis: CW, MW, FP, AKS.